These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30899983)

  • 21. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
    Mizukami T; Miyaji T; Narita Y; Matsushima T; Ogura T; Miyagaki H; Kawabata R; Horie Y; Kawaguchi T; Muro K; Hara H; Yamaguchi T; E Nakajima T
    Future Oncol; 2021 Jul; 17(19):2431-2438. PubMed ID: 33764163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
    Kawai S; Fukuda N; Yamamoto S; Mitani S; Omae K; Wakatsuki T; Kato K; Kadowaki S; Takahari D; Boku N; Muro K; Machida N
    BMC Cancer; 2020 Apr; 20(1):338. PubMed ID: 32316940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.
    Kim ST; Sa JK; Oh SY; Kim K; Hong JY; Kang WK; Kim KM; Lee J
    Genome Med; 2021 Jan; 13(1):11. PubMed ID: 33494793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
    J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy.
    Kakuta T; Yabusaki H; Bamba T; Aizawa M; Nogami H; Nomura T; Matsuki A; Maruyama S; Takii Y; Nakagawa S
    Int J Clin Oncol; 2021 Apr; 26(4):684-693. PubMed ID: 33389346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer.
    Aktaş SH; Akbulut Yazici HO; Zengin N; Akgün HN; Üstüner Z; Içli F
    Turk J Med Sci; 2017 Apr; 47(2):399-406. PubMed ID: 28425270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
    Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.
    Matsubara Y; Ando T; Hosokawa A; Mihara H; Takagi H; Nakata N; Yoshita H; Nanjo S; Kajiura S; Fujinami H; Sugiyama T
    Intern Med; 2018 Mar; 57(5):671-675. PubMed ID: 29151523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Moore M; Gill S; Asmis T; Berry S; Burkes R; Zbuk K; Alcindor T; Jeyakumar A; Chan T; Rao S; Spratlin J; Tang PA; Rothenstein J; Chan E; Bendell J; Kudrik F; Kauh J; Tang S; Gao L; Kambhampati SR; Nasroulah F; Yang L; Ramdas N; Binder P; Strevel E
    Ann Oncol; 2016 Dec; 27(12):2216-2224. PubMed ID: 27733377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
    Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy].
    Kimura Y; Makari Y; Mikami J; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Fujita J; Furukawa H; Yasuda T
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1080-1082. PubMed ID: 29394540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer.
    Liepa AM; Cui ZL; Beyrer JK; Hadden EL; Chatterjee A
    Future Oncol; 2023 Jun; 19(18):1277-1291. PubMed ID: 37194743
    [No Abstract]   [Full Text] [Related]  

  • 36. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Smyth EC; Tarazona N; Chau I
    Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals.
    Hashida S; Tanaka N; Takahashi Y; Onoda Y; Colvin HS; Ohashi R; Okamoto K
    Acta Med Okayama; 2021 Apr; 75(2):133-138. PubMed ID: 33953419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer.
    Sorokin M; Poddubskaya E; Baranova M; Glusker A; Kogoniya L; Markarova E; Allina D; Suntsova M; Tkachev V; Garazha A; Sekacheva M; Buzdin A
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32060041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
    Chen Y; Katayose T; Nagaoka S; Piao Y; Yamaguchi K; Asou H
    Gastric Cancer; 2021 Nov; 24(6):1320-1329. PubMed ID: 34050432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.